scanX
Lupin
add_icon

Lupin

2,219.40
-9.30
(-0.42%)
Market Cap
1,01,381.93 Cr
PE Ratio
21.81
Volume
5,09,573.00
Day High - Low
2,241.20 - 2,210.40
52W High-Low
2,263.00 - 1,795.20
ann
There are 1 new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,01,381.93 Cr
EPS
71.95
PE Ratio
21.81
PB Ratio
5.19
Book Value
595.67
EBITDA
5,479.10
Dividend Yield
0.54 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
19.12
Debt to Equity
0.27
Analyst Rating and Forecast
- By Refinitiv from35 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+62.86 %
+62.86 %
Hold
Hold+28.57 %
+28.57 %
Sell
Sell+8.57 %
+8.57 %
Forecast For
Actual

Company News

View All News
Caret
positive
Lupin Appoints Anand Kripalu as Independent Director7 days ago
Lupin Limited successfully passes special resolution appointing Mr. Anand Kripalu as Independent Director through postal ballot with 96.53% votes in favor from 90.17% shareholder participation.
neutral
Lupin Allots 75,273 Equity Shares Under ESOP7 days ago
Lupin Limited allotted 75,273 equity shares to employees under its stock option plan on February 13, 2026, increasing paid-up capital to ₹91,40,86,438 with 45,70,43,219 total equity shares.
positive
Lupin Reports Strong Q3 FY26 Results with 26.4% Growth8 days ago
Lupin Limited delivered robust Q3 FY26 performance with sales of ₹71,005 Mn, up 26.4% YoY. EBITDA surged 68.6% to ₹23,766 Mn with margin expansion to 33.5%. US market led growth with 54% increase.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,724.40
#1 4,13,741.32
37.53
#1 54,729.00
9.71
#1 10,980
16.07
58.16
Divis Laboratories
6,291.00
1,67,006.28
67.40
9,712.00
18.67
2,191
-1.02
53.89
Torrent Pharmaceuticals
4,241.70
1,43,558.40
62.90
11,539.40
6.99
1,911
26.24
66.58
Cipla
1,341.10
1,08,330.28
23.68
28,409.50
7.12
5,291
-57.18
43.41
Dr Reddys Laboratories
1,280.40
1,06,866.07
19.34
33,741.20
16.73
5,725
-15.28
60.10
Lupin
2,219.40
#6 1,01,381.93
#4 21.81
#6 22,909.50
#5 13.74
#6 3,306
#1 37.44
57.52
Zydus Life Science
900.75
90,636.53
#1 18.06
23,511.00
18.55
4,615
-0.32
49.52
Mankind Pharma
2,024.30
83,564.13
46.65
12,744.20
#1 20.90
2,007
7.65
38.95
Aurobindo Pharma
1,158.80
67,303.29
19.60
32,345.60
9.43
3,484
7.59
47.48
Alkem Laboratories
5,392.00
64,469.45
26.53
13,458.30
3.70
2,216
1.90
37.57

Automatic Screeners on ScanX

Community
1% near 52 Week High
Growth Rate
Revenue Growth
13.74 %
Net Income Growth
70.82 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
22.54 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
3,071
3,157
3,250
3,417
4,144
4,424
4,243
4,511
4,209
3,839
3,952
3,929
4,125
3,960
4,122
3,872
3,922
3,922
4,007
3,844
4,084
3,513
3,807
3,939
3,808
4,265
4,076
4,122
3,880
3,610
4,106
4,263
4,368
4,765
4,980
5,109
4,924
5,582
5,539
5,672
5,619
6,243
6,921
7,215
Expenses
2,289
2,331
2,667
2,702
2,883
3,157
3,260
3,264
3,472
3,104
3,099
3,287
4,789
3,329
3,401
3,608
3,107
3,131
3,788
3,629
3,320
3,040
3,254
3,239
3,066
3,306
5,415
3,791
3,615
3,512
3,693
3,790
3,852
3,958
4,121
4,160
3,964
4,359
4,332
4,412
4,346
4,541
4,706
5,332
EBITDA
783
825
583
715
1,261
1,268
983
1,246
737
735
853
642
-665
631
721
264
814
791
219
215
763
473
553
700
742
960
-1,339
331
265
98
414
473
515
807
859
950
960
1,223
1,207
1,261
1,273
1,702
2,215
1,883
Operating Profit %
25 %
24 %
16 %
19 %
30 %
27 %
23 %
26 %
17 %
18 %
20 %
16 %
-20 %
12 %
13 %
6 %
18 %
18 %
1 %
2 %
12 %
12 %
14 %
17 %
18 %
22 %
-35 %
7 %
6 %
3 %
10 %
11 %
11 %
17 %
17 %
18 %
19 %
21 %
21 %
21 %
22 %
26 %
31 %
25 %
Depreciation
107
101
116
122
149
203
211
231
267
261
272
280
273
259
266
219
219
250
253
253
214
215
213
244
216
209
919
203
327
193
204
220
264
235
248
257
457
248
257
272
393
299
317
313
Interest
3
7
24
10
31
35
29
48
41
44
48
54
59
69
74
79
84
84
83
89
107
44
34
31
32
34
34
33
42
43
55
84
93
86
81
74
71
68
71
67
89
92
108
115
Profit Before Tax
697
792
581
781
1,170
1,156
822
1,045
520
494
611
383
-941
384
441
93
591
518
-54
-73
496
273
360
525
518
751
-2,205
167
-85
2
210
246
259
559
630
736
498
993
1,055
1,071
896
1,416
2,007
1,522
Tax
136
224
158
255
417
273
159
410
137
137
154
161
-163
181
173
245
294
216
70
767
105
164
147
84
54
202
-110
-382
427
89
75
89
16
106
134
117
130
188
195
212
114
194
522
342
Net Profit
561
568
422
526
753
883
663
636
384
357
457
222
-778
203
269
-152
296
303
-123
-840
391
109
214
441
464
548
-2,095
549
-512
-87
135
158
242
453
495
619
368
806
860
859
782
1,222
1,485
1,181
EPS in ₹
12.17
12.65
9.34
11.67
16.63
19.57
14.69
14.04
8.42
7.93
10.07
4.91
-17.33
6.40
5.88
-3.37
6.55
6.69
-2.72
-18.56
8.64
2.36
4.66
9.67
10.15
11.96
-46.22
12.01
-11.40
-1.96
2.85
3.38
5.19
9.94
10.76
13.47
7.89
17.58
18.70
18.75
16.93
26.70
32.36
25.74
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
9,719
Current Assets
7,832
9,887
11,953
12,210
13,854
15,413
13,986
12,458
12,451
13,448
16,799
Capital Work in Progress
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
517
Investments
1,656
16
2,136
262
2,296
2,374
2,455
900
517
1,075
1,146
Other Assets
6,538
11,189
11,305
13,084
12,928
13,732
12,209
12,393
12,846
13,272
17,823
Total Liabilities
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
Current Liabilities
3,729
5,061
6,121
5,096
6,130
9,225
8,436
8,498
9,265
8,502
8,961
Non Current Liabilities
510
6,368
6,955
7,593
8,030
3,178
1,316
1,101
1,148
1,122
2,949
Total Equity
8,898
11,196
13,532
13,617
13,789
12,581
13,858
12,222
12,543
14,374
17,294
Reserve & Surplus
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
17,112
Share Capital
90
90
90
90
91
91
91
91
91
91
91
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1,502
-1,315
2,019
729
-872
1,685
-1,303
87
273
-248
560
Investing Activities
-1,034
-6,769
-2,527
470
-3,283
1,107
-1,240
1,292
-1,287
-1,712
-4,172
Operating Activities
2,733
-382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
3,000
Financing Activities
-197
5,836
433
-1,492
744
-891
-1,885
-1,572
-337
-2,184
1,732
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
46.86 %
46.84 %
46.83 %
46.81 %
46.78 %
47.10 %
47.11 %
47.10 %
47.08 %
47.07 %
47.05 %
47.04 %
47.01 %
46.98 %
46.96 %
46.95 %
46.92 %
46.90 %
46.90 %
46.89 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.11 %
18.28 %
19.32 %
21.50 %
22.04 %
21.46 %
21.25 %
20.49 %
21.49 %
DIIs
22.08 %
21.68 %
24.38 %
24.76 %
26.84 %
26.82 %
27.54 %
29.38 %
29.21 %
28.98 %
29.42 %
29.73 %
27.76 %
26.78 %
25.09 %
24.74 %
25.41 %
25.56 %
26.55 %
25.58 %
Government
0.29 %
0.28 %
0.28 %
0.28 %
0.29 %
0.29 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
10.02 %
9.91 %
10.18 %
9.99 %
8.53 %
8.59 %
8.41 %
8.06 %
7.86 %
7.06 %
6.24 %
5.87 %
5.70 %
5.65 %
5.29 %
5.17 %
5.10 %
5.23 %
5.12 %
5.10 %
Others
20.75 %
21.29 %
18.34 %
18.16 %
17.57 %
17.19 %
16.94 %
15.45 %
15.85 %
16.89 %
17.27 %
1.23 %
1.23 %
1.26 %
1.15 %
1.10 %
1.10 %
1.05 %
0.94 %
0.93 %
No of Share Holders
0
2,93,782
3,02,292
3,61,288
3,61,862
3,78,547
3,82,828
3,78,011
3,60,677
3,22,678
2,89,074
2,81,542
2,80,248
2,88,537
2,79,280
2,81,988
2,83,210
2,86,604
2,80,256
2,88,931

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 7.5 5 5 6 6.5 4 4 8 12 0.00
Dividend Yield (%) 1.02 0.68 0.85 0.59 0.87 0.61 0.25 0.39 0.54 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 Jul 2021 DIVIDEND Dividend
₹ 6.50 /share
 27 Jul 2021 1,212.25 1,111.60
15 Jul 2022 DIVIDEND Dividend
₹ 4.00 /share
 14 Jul 2022 683.30 643.20
14 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
 14 Jul 2023 732.25 930.75
16 Jul 2024 DIVIDEND Dividend
₹ 8.00 /share
 16 Jul 2024 1,655.25 1,832.10
02 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 02 Aug 2024 1,778.90 1,953.55
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 2,151.95 2,166.05
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Feb 2025 2,134.25 2,169.40
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 May 2025 2,107.70 2,063.00
25 Jul 2025 DIVIDEND Dividend
₹ 12.00 /share
 25 Jul 2025 2,063.00 1,943.40
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Aug 2025 1,930.85 1,882.20
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Aug 2025 1,894.70 1,918.00
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2025 1,943.35 1,997.00
12 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Feb 2026 2,150.50 2,209.10

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome7 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report7 days ago
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot7 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS7 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation8 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
Board Meeting Outcome for Outcome Of The Board Meeting For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.8 days ago
Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
Settlement And License Agreement10 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 02, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 02, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2026
Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.Jan 28, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 21, 2026
ESG Rating By ESG Risk Assessments And Insights Limited.Jan 19, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 15, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJan 14, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateJan 06, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 29, 2025
Closure of Trading WindowDec 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 12, 2025
Newspaper Publication For The Information Regarding Special Window For Re-Lodgement For Transfer Request Of Physical Shares.Dec 11, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 10, 2025
ESG Rating By NSE Sustainability Ratings & Analytics Limited.Dec 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Dec 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 28, 2025
U.S. FDA Has Conducted An Inspection At Companys Manufacturing Facility Located At Goa India.Nov 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 12, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Abakkus Flexi Cap Fund Direct - Growth
1.92%
250074
1.92%
1.92%
UTI Multi Cap Fund Direct-Growth
0.99%
85000
0.99%
0.99%
ICICI Prudential Active Momentum Fund Direct-Growth
2.46%
42198
0.65%
2.46%
Bandhan Multi-Factor Fund Direct - Growth
2.65%
21746
0.68%
-0.86%
JioBlackRock Flexi Cap Fund Direct-Growth
1.02%
-16441
-0.17%
-0.29%
WhiteOak Capital Equity Savings Fund Direct - Growth
0.00%
-9350
-0.89%
-0.99%
Kotak Active Momentum Fund Direct-Growth
1.96%
-1542
0.09%
0.24%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
1.40%
1265
0.07%
0.09%
Franklin India Multi-Factor Fund Direct - Growth
1.30%
1148
0.02%
1.30%
Tata Nifty Midcap 150 Index Fund Direct-Growth
1.41%
-636
0.08%
0.09%
DSP Nifty 500 Index Fund Direct-Growth
0.27%
146
0.27%
0.27%
Kotak Nifty Midcap 150 Index Fund Direct - Growth
1.40%
124
0.07%
0.09%
DSP Nifty Healthcare Index Fund Direct-Growth
5.56%
111
0.36%
0.56%
DSP Nifty Midcap 150 Index Fund Direct - Growth
1.40%
70
0.07%
1.40%
Groww Nifty Midcap 150 Index Fund Direct - Growth
1.40%
60
0.07%
0.08%
Nippon India Nifty India Manufacturing Index Fund Direct - Growth
1.42%
-30
0.06%
0.08%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.92%
25
0.05%
0.92%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.26%
12
0.01%
0.02%
ITI Arbitrage Fund Direct - Growth
0.00%
0
0.00%
0.00%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.27%
0
0.00%
0.01%
Axis Large & Mid Cap Fund Direct-Growth
0.68%
0
0.00%
0.03%
Axis Large Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Midcap Direct Plan-Growth
1.02%
0
0.00%
0.05%
Axis Momentum Fund Direct - Growth
0.00%
0
0.00%
0.00%
Axis Multi Asset Allocation Direct Plan -Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
59.91
ATR(14)
Less Volatile
47.93
STOCH(9,6)
Neutral
69.40
STOCH RSI(14)
Neutral
79.89
MACD(12,26)
Bullish
3.09
ADX(14)
Weak Trend
12.95
UO(9)
Bearish
55.36
ROC(12)
Uptrend But Slowing Down
1.96
WillR(14)
Overbought
-18.56
Bearish
4
Neutral
4
Bullish
1

About Lupin

Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The...more
Website
https://www.lupin.com/
Chairperson NameM D Gupta
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104